Free Trial
TSE:FRX

Fennec Pharmaceuticals (FRX) Stock Price, News & Analysis

Fennec Pharmaceuticals logo
C$12.50 +0.49 (+4.08%)
As of 08/27/2025 03:45 PM Eastern

About Fennec Pharmaceuticals Stock (TSE:FRX)

Key Stats

Today's Range
C$12.50
C$12.50
50-Day Range
C$10.77
C$12.70
52-Week Range
C$5.65
C$12.99
Volume
1,166 shs
Average Volume
1,036 shs
Market Capitalization
C$241.06 million
P/E Ratio
N/A
Dividend Yield
2.02%
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

Receive FRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

FRX Stock News Headlines

Wedbush Predicts Lower Earnings for Fennec Pharmaceuticals
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel
Fennec Pharmaceuticals Inc. (FENC) - Yahoo Finance
See More Headlines

FRX Stock Analysis - Frequently Asked Questions

Fennec Pharmaceuticals' stock was trading at C$8.87 on January 1st, 2025. Since then, FRX shares have increased by 40.9% and is now trading at C$12.50.

Fennec Pharmaceuticals Inc. (TSE:FRX) released its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.10. Fennec Pharmaceuticals had a negative net margin of 2.30% and a positive trailing twelve-month return on equity of 29.94%.

Shares of FRX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fennec Pharmaceuticals investors own include Tilray Brands (TLRY), Aurora Cannabis (ACB), Encanto Potash (EPO), Adherex Technologies (FENC), Ocugen (OCGN), Passport Potash (PPI) and Workhorse Group (WKHS).

Company Calendar

Last Earnings
11/07/2024
Today
8/29/2025

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
TSE:FRX
CIK
N/A
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
C($0.06)
Trailing P/E Ratio
N/A
Forward P/E Ratio
20.70
P/E Growth
N/A
Net Income
-C$800.44 thousand
Net Margins
-2.30%
Pretax Margin
N/A
Return on Equity
29.94%
Return on Assets
8.88%

Debt

Debt-to-Equity Ratio
-620.83
Current Ratio
7.80
Quick Ratio
10.17

Sales & Book Value

Annual Sales
C$34.86 million
Price / Sales
6.91
Cash Flow
C$1.07 per share
Price / Cash Flow
11.66
Book Value
C($0.19) per share
Price / Book
-65.99

Miscellaneous

Outstanding Shares
19,284,690
Free Float
N/A
Market Cap
C$241.06 million
Optionable
Not Optionable
Beta
0.25
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (TSE:FRX) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners